The Trump administration has pledged $812 million (AED 2.98 billion) to boost the US manufacturing of medicines needed to treat the coronavirus.
It's aimed to end dependence on other countries, and boost their own supply chain.
The four-year contract, worth $354 million, which has been awarded to Virginia-based Phlow Corp can be extended to a total of $812 million over 10 years.
It will develop essential drugs and not vaccines, officials explained.
"For far too long, we've relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America's health, safety, and national security at grave risk," Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, said in a statement.
US Senate passes Trump's tax-cut, spending bill; sends to House
France shuts schools as heatwave grips Europe
Blow for Thailand's government as court suspends PM from duty
Trump signs order lifting sanctions on Syria, White House says
Suspect in murders of four Idaho college students to plead guilty
